MK-8776 (SCH 900776)

Catalog No.S2735

MK-8776 (SCH 900776) Chemical Structure

Molecular Weight(MW): 376.25

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.

Size Price Stock Quantity  
USD 210 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

6 Customer Reviews

  • Western blots of proteins associated with Chk1 activation and apoptosis.

    Biomaterials, 2018, 182:35-43. MK-8776 (SCH 900776) purchased from Selleck.

    MCF7 cells were seeded in 60 mm dishes and were pretreated with the specified inhibitor 1 h before stimulation with either vehicle or doxorubicin. Twenty-four hours after treatment, cells were collected and immunoblotted for nSMase2 and actin.

    Cell Death Dis, 2015, 6:e1947.. MK-8776 (SCH 900776) purchased from Selleck.

  • SK-MES-1 cells were treated with 5 nM gemcitabine for 4 hours. The drug was then replaced with MK-8776 at the indicated doses and the cells harvested after an additional 6 hours. Cell lysates were analyzed by Western blotting for the indicated protein.

    Sci Rep, 2017, 7(1):15031. MK-8776 (SCH 900776) purchased from Selleck.

    (A, B) In the three TNBC cell lines, the numbers of autophagy-related spots were significantly increased in IR-alone group, and this effect was significantly suppressed by MK-8776 (IR vs MK-8776+IR: 65±23 vs 13±8, P<0.0001 in MDA-MB-231; 57±32 vs 18±7, P=0.0014 in BT-549; 43±35 vs 14±10, P=0.021 in CAL-51).

    Acta Pharmacol Sin, 2017, 38(4):513-523. MK-8776 (SCH 900776) purchased from Selleck.

  • HT29 cells were treated with 1 μM V411, 3 μM LY2603618 (LY), 3 μM MK-8776 (MK), 3 μM GNE-900 (GNE) or 0.3 μM ARRY-1A (ARRY) for 24 h. The fraction of γH2AX, pRPA32 (S4/S8), pChk1 (S317) or pChk2 (T68) positive nuclei were determined by single cell immunofluorescent imaging (n=4, mean ± SD). B. HT29 cells were treated as above for 2 or 24 h. Cell lysates were probed with the indicated antibodies by immunoblotting.

    Oncotarget, 2016, 7(51):85033-85048. MK-8776 (SCH 900776) purchased from Selleck.

    Hela cell was trypsinized and plated at 30% confluence in DMEM. 16 hours later, MK-8776 (SCH900776) was added at final concentrations of 0, 5, 10 and 25uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- CHK1, pS345-CHK1 and beta-actin (internal control) antibodies.

    MK-8776 (SCH 900776) purchased from Selleck.

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
Targets
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
3 nM 0.16 μM
In vitro

SCH 900776 is a less potent inhibitor of Chk2 and CDK2 with IC50 of 1.5 μM and 0.16 μM, respectively. SCH 900776 shows no significant inhibition of cytochrome P450 human liver microsomal isoforms 1A2, 2C9, 2C19, 2D6, and 3A4. SCH 900776 induces a dose-dependent loss of DNA replication capability 24 hours after hydroxyurea exposure. SCH 900776 enhances the γ-H2AX response of hydroxyurea, 5-fluoruracil, and cytarabine. In combination with an antimetabolite, SCH 900776 induces accumulation of γ-H2AX within 2 hours, indicative of replication fork collapse and double stranded DNA breaks. Additionally, SCH 900776 suppresses accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner. Exposure of proliferating WS1 cells to SCH 900776 is associated with rapid, dose-dependent accumulation of Chk1 pS345, indicating that cycling populations of normal cells induce Chk1 pS345 following exposure to SCH 900776 as part of a futile cycle, perhaps driven by AT-family kinases and DNA-PK.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT0NlAxNzJyMECgcm0> NYjLRY5VOjRiaB?= M37JU4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MnewNlQ{PTl3Mk[=
HCT115 M1vWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7nN2h3OjByL{KwNFAhdk1? M{fGd|I1KGh? M3;UdoRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MYSyOFM2QTV{Nh?=
SW620 NF3JTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSyNFAwOjByMDDuUS=> MkLGNlQhcA>? M2PTOYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= M{jKelI1OzV7NUK2
IGROV-1 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\sclQzODBxMkCwNEBvVQ>? NUTreXBGOjRiaB?= M{G5WYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= M1vINFI1OzV7NUK2
HCT116 M3TM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXsWnMzODBxMkCwNEBvVQ>? Mli4NlQhcA>? NX7WcJdl\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NH[4WFkzPDN3OUWyOi=>
MCF10A NHH1VY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u1clIxOC9{MECwJI5O MYSyOEBp NV\pfGhp\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l MlLMNlQ{PTl3Mk[=
MiaPaCa-2 M17UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPDNlAxNzJyMECgcm0> NG\XfWozPCCq M{npXoRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NGrRR4IzPDN3OUWyOi=>
MDA-MB-231 M4fKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TQeFIxOC9{MECwJI5O NE\DcXYzPCCq Mk\v[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n M4e1VFI1OzV7NUK2
HCC2998 NGe3Rm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKyNFAwOjByMDDuUS=> MVKyOEBp MXLk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MU[yOFM2QTV{Nh?=
U87 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnjNFdVOjByL{KwNFAhdk1? NUfXXZlkOjRiaB?= NEX2[ZFl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NU\w[IMyOjR|NUm1NlY>
MDA-MB-435 NGX6e2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHLNlAxNzJyMECgcm0> MoXrNlQhcA>? NVq4eYFN\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NXP0SI05OjR|NUm1NlY>
SNB19 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW1[4Z6OjByL{KwNFAhdk1? NU\xSWFmOjRiaB?= NGPVd2Jl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= M1[3c|I1OzV7NUK2
U20S NX2ySoFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\aNlAxNzJyMECgcm0> M3;YW|I1KGh? MkXX[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n M3LDdFI1OzV7NUK2
A498 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[yNFAwOjByMDDuUS=> MXyyOEBp NWrhdpJR\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NUT4PG52OjR|NUm1NlY>
TK10 NWXSRYVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLYT2V5OjByL{KwNFAhdk1? NYP6UGtuOjRiaB?= NFG1NXhl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= M4LhXFI1OzV7NUK2
AsPC-1 NVvid2J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKyNFAwOjByMDDuUS=> MnH2NlQhcA>? MXjk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MnvUNlQ{PTl3Mk[=
H23 NH7Lc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXexO5FrPTByIH7N MnzLNlQhcA>? MorRSG1UVw>? NV73W3J4\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{BRVVh? NXrEemJWOjRzMUO1OFk>
H1437 M3rMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H1c|UxOCCwTR?= MXqyOEBp MlnhSG1UVw>? Mo[3[Y5p[W6lZYOgeIhmKGOqZX3vd4Vve2m2aYrheIlwdiC2bzDQUXg> NILHdXkzPDFzM{W0PS=>
H1993 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS4OVAxKG6P NXf5NnhWOjRiaB?= M{\mW2ROW09? NXu4Rngy\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{BRVVh? M3\EZVI1OTF|NUS5
H1299 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzCUGo2ODBibl2= M3HtdlI1KGh? M4LpPGROW09? MYTlcohidmOnczD0bIUh[2inbX;z[Y5{cXSrenH0bY9vKHSxIGDNXC=> M{XqRlI1OTF|NUS5
AsPC-1 NYP6Tmw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnZO4h5OTBvMUCwNEBvVQ>? MUOyOE01QGh? NUH1VnRJ\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{Bo\W2laYThZolv\Q>? MYSyN|gxPDR{Mh?=
MiaPaCa-2 MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7iRWIyOC1zMECwJI5O MYSyOE01QGh? M3TKPYVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> MofENlM5ODR2MkK=
BxPC-3 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv5NVAuOTByMDDuUS=> M4nqTFI1NTR6aB?= NWnrToZm\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{Bo\W2laYThZolv\Q>? MXWyN|gxPDR{Mh?=
SKOV3 NEjXbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKwMlMhyrWP MmjEPEBl NGr3[op{\W6|aYTpfoV{KHSqZTDj[YxtKGyrbnXzJJRwKGenbXPpeIFjcW6nwrC= NXrHc2RwOjN3NEiyOlk>
OVCAR-8 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHWwVpgxNjNiwsXN NXrreVhDQCCm M2fnZZNmdnOrdHn6[ZMhfGinIHPlcIwhdGmwZYOgeI8h\2WvY3n0ZYJqdmYEoB?= MkfaNlM2PDh{Nkm=
MV-4-11 MVHBdI9xfG:|aYOgRZN{[Xl? M2PLVVExOC15MECgcm0> MVm0PEBp NUi1enljcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> M1nzVlI{PTN4N{Kx
U937 MkfxRZBweHSxc3nzJGF{e2G7 MUexNFAuPzByIH7N MUO0PEBp NGP4[5RqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MXmyN|U{Pjd{MR?=
MOLM-13  NYLWbYQ{SXCxcITvd4l{KEG|c3H5 Ml\SNVAxNTdyMDDuUS=> NHzRZ4U1QCCq MmTBbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MXiyN|U{Pjd{MR?=
A2058  M1TIRmNmdGxiVnnhZoltcXS7IFHzd4F6 MkniN|cvPS1|MECgcm0> NYfoSWhUPzJiaB?= NHnMZ4lFVVOR MYny[YR2[2W|IITo[UBOUy1zN{e1JGVEPTEEoHL5JFUu\m:uZDD0c{BidiCjdnXyZYdmKG:oIES1JI5O MX6yN|E1QDZ6NB?=
H2009 NFXudZlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX3XWFZOPTByIH7N MWO3NkBp M1XDd2ROW09? MXHy[ZN2dHS|IHnuJGcyN1NvcHjhd4Uh[WOldX31cIF1cW:wIHPvcYJqdmWmIIfpeIghVUtvMUe3OS=> NH\UfGQzOzF2OE[4OC=>
Su.86.86 M{nSTmNmdGxiVnnhZoltcXS7IFHzd4F6 MkjOOVAxKG6P NWHib3RxPzJiaB?= NEDFXZFFVVOR Ml7jdoV{fWy2czDpckBIOS:VLYDoZZNmKGGlY4XteYxifGmxbjDjc41jcW6nZDD3bZRpKE2NLUG3O|U> NXrUZVVTOjNzNEi2PFQ>
HRE MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1j2U|UxOCCwTR?= NUO5c2syPzJiaB?= MW\EUXNQ NYC4XGhSemW|dXz0d{BqdiCJMT;TMZBp[XOnIHHjZ5VufWyjdHnvckBkd22kaX7l[EB4cXSqIF3LMVE4PzV? M2nvelI{OTR6Nki0
HMEC MnrjR4VtdCCYaXHibYxqfHliQYPzZZk> NXXlTJI{PTByIH7N NVWxTGZ3PzJiaB?= M4DuUGROW09? MWDy[ZN2dHS|IHnuJGcyN1NvcHjhd4Uh[WOldX31cIF1cW:wIHPvcYJqdmWmIIfpeIghVUtvMUe3OS=> NE\Eb2YzOzF2OE[4OC=>
U2OS  NYPEVoJkTnWwY4Tpc44hSXO|YYm= NGi5UXEzKML3TR?= M4HD[FAuOjRiaB?= NVnxb|h5cW6mdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMTDheEB{\XKrbnWgN|Q2KGG2IHLveIgh[2:wY3XueJJifGmxboOgZZMh\WG{bImgZZMhOiCqIHHmeIVzKGGmbXnubZN1emG2aX;u MXWyNlk{PzF2Nx?=
U2OS  NUf6[GF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm2XW8xNTFyINM1US=> NY\Pc|ZGOjRxNEigbC=> MlrzbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MVKyNlk{PzF2Nx?=
U937 NX;H[5JiTnWwY4Tpc44hSXO|YYm= M3j0R|ExOC13MECgcm0> NFPYN3E1KGkEoB?= NGnYXHRl\WO{ZXHz[ZMhfGinIHP5eIFz[WKrbnWtbY5lfWOnZDDDbIsyKGG3dH;wbI9{eGixconsZZRqd25iYYSgV4VzOjl4wrDhcoQheHKndnXueJMhS2SlMkXBJIRwf26{ZXf1cIF1cW:w M3jlRVIzQDZ7OE[5
U937 MWrGeY5kfGmxbjDBd5NigQ>? MVuxNFAhdk1? NUnNc45uPCCqwrC= NVvadGR7emW4ZYLz[ZMhfGinIHP5eIFz[WKrbnWtbY5lfWOnZDDpcohq[mm2aX;uJI9nyqB|SD30bJlucWSrbnWgbY5kd3Kyb4LheIlwdiCrboTvJGRPSQ>? M{fRbFIzQDZ7OE[5
U937 MVvGeY5kfGmxbjDBd5NigQ>? M1zSbVExOC13MECgcm0> MX[0JIjDqA>? NIq1bXdqdmS3Y3XzJIlv[3KnYYPl[EBxcG:|cHjvdplt[XSrb36gc4YhUDKDWB?= MmPqNlI5Pjl6Nkm=
HL-60 MV\BdI9xfG:|aYOgRZN{[Xl? NULZOolROzBxMUCwM|MxOCCwTR?= NEnBUFczPCCq M1XhR2ROW09? NITkNYxmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{ NFnwPFIzOjh4OUi2PS=>
ML-1 MY\BdI9xfG:|aYOgRZN{[Xl? M1vI[FI2NzVyL{GwNEBvVQ>? NWL5NW1GOjRiaB?= MoO2SG1UVw>? NV7ydIhN\W6qYX7j[ZMh[3m2YYLhZolv\S2rbnT1Z4VlKGGyb4D0c5Nqew>? NWmxRmZHOjJ6Nkm4Olk>
HCT116 NEe0O3NHfW6ldHnvckBCe3OjeR?= M{XYdlEhyrWP NY[xelFYOjRiaB?= M{DPSoFjem:pYYTld{Bw\iClZXzsJIN6[2ynIHHydoV{fMLi M3LwOFIzPTFyNU[w
U2OS NGXQUFhHfW6ldHnvckBCe3OjeR?= NGPxVmsyKML3TR?= MXKyOEBp NHu3N5Ni[nKxZ3H0[ZMhd2ZiY3XscEBkgWOuZTDhdpJme3UEoB?= MU[yNlUyODV4MB?=

... Click to View More Cell Line Experimental Data

In vivo Administered 30 minutes after gemcitabine, 4 mg/kg SCH 900776 is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or SCH 900776 alone. Dose escalation of SCH 900776 (16 mg/kg and 32 mg/kg) induces incremental improvements in tumor response. Importantly, doses of SCH 900776 associate with robust biomarker activation and improved tumor response are not associated with enhanced toxicity of gemcitabine on hematological parameters in BALB/c mice. [1]

Protocol

Animal Research:[1]
+ Expand
  • Animal Models: Female nude mice injected subcutaneously with A2780 or MiaPaCa2 cells
  • Formulation: Formulated in 20% hydroxypropyl β-cyclodextrin
  • Dosages: ~50 mg/kg
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (7.97 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% propylene glycol
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.25
Formula

C15H18BrN7

CAS No. 891494-63-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870596 Completed Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia National Cancer Institute (NCI) May 2013 Phase 2
NCT01870596 Completed Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia National Cancer Institute (NCI) May 2013 Phase 2
NCT00907517 Terminated Myelogenous Leukemia Acute|Leukemia Lymphocytic Acute|Leukemia Lymphoblastic Acute Philadelphia-Positive|Myelogenous Leukemia Chronic Aggressive Phase Merck Sharp & Dohme Corp. July 29 2009 Phase 1
NCT00907517 Terminated Myelogenous Leukemia Acute|Leukemia Lymphocytic Acute|Leukemia Lymphoblastic Acute Philadelphia-Positive|Myelogenous Leukemia Chronic Aggressive Phase Merck Sharp & Dohme Corp. July 29 2009 Phase 1
NCT00779584 Completed Hodgkin Disease|Lymphoma Non-Hodgkin|Neoplasms Merck Sharp & Dohme Corp. October 17 2008 Phase 1
NCT00779584 Completed Hodgkin Disease|Lymphoma Non-Hodgkin|Neoplasms Merck Sharp & Dohme Corp. October 17 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

  • Answer:

    Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Related Chk Products4

Tags: buy MK-8776 (SCH 900776) | MK-8776 (SCH 900776) supplier | purchase MK-8776 (SCH 900776) | MK-8776 (SCH 900776) cost | MK-8776 (SCH 900776) manufacturer | order MK-8776 (SCH 900776) | MK-8776 (SCH 900776) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID